Zeliang Zhao1#, Chao Liu1#, Haiwei Wu1, Haiguang Zhao2 and Jiawei Zheng1*
1Department of Oromaxillofacial, Head and Neck Oncology, Shanghai Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, China
2Department of Plastic and Aesthetic Surgery, Huadong Hospital Affiliated to Fudan University, China #These authors contributed equally to this work
Purpose: Sclerotherapy with polidocanol foam has frequently been used for the chronic venous disease, hemangiomas and other vascular malformations, but less report on the evaluation of pyogenic granulomas has been documented. The aim of this study was to evaluate the efficacy and safety of the sclerotherapy with polidocanol foam for pyogenic granulomas. Patients and Methods: In this study, we summarized our experiences of treating 52 patients with pyogenic granuloma by local injection of 1% polidocanol and evaluated the curative effect and safety. The follow-up period after treatment ranged from 5 months to 18 months and the median duration was 9 months. Descriptive statistics were computed. Results: 51 of the 52 patients received complete removal of the tumor, without exudation, pigmentation and scarring. Follow-up 5-18 months, 1 of the 51 patients showed lesion recurrence and other 50 patients have reached the standard of cure. No bleeding or infection was found in the wound and no noticeable scar was observed. Conclusion: Our study indicated that sclerotherapy with polidocanol foam achieved considerable response with low recurrences rate and no complications and is a promising perspective treatment for pyogenic granuloma.
Pyogenic granuloma; Sclerotherapy, Polidocanol; Effectiveness
Zhao Z, Liu C, Wu H, Zhao H, Zheng J. Sclerotherapy with Polidocanol Foam is a Promising Perspective Treatment for Pyogenic Granuloma: A Retrospective Analysis in 52 Cases. Clin Surg. 2019; 4: 2680..